Moderna’s new technology centre in Melbourne is combining advanced mRNA manufacturing with a future-ready model for health security and innovation.
When the COVID-19 pandemic exposed the vulnerabilities of global supply chains, few countries felt the impact more than Australia. The country’s vaccine rollout relied heavily on overseas supply, sparking a reckoning on health security and sovereign capability. Out of that moment came a national ambition to build domestic resilience – and at the heart of it stands the Moderna Technology Centre in Melbourne (MTC-M), the Southern Hemisphere’s first end-to-end mRNA manufacturing facility.
For Emma Harrington, vice-president and site head at Moderna Australia, the creation of this facility was both a necessity and a national opportunity.
“Australia’s experience during COVID-19 really showed the need to have sovereign vaccine capability,” she said. “From reviews into the pandemic response, both federal and state governments recognised the importance of building domestic capability to ensure future health security.”
Melbourne’s deep research ecosystem, stable regulatory environment and commitment to innovation made it a natural choice. Supported through a partnership between the Federal and Victorian governments, the facility was designed to anchor a new high-tech industry with lasting health and economic benefits for decades to come.
Building a sovereign base for rapid response
Moderna’s MTC-M was established within the Monash Technology Precinct, a growing biomedical hub in Melbourne’s southeast. Operationally complete in December 2024, the site represents the first time Australia has had the ability to produce mRNA vaccines from end to end – from drug substance through to fill-and-finish.
The facility has the capacity to produce up to 100 million vaccine doses per year in a pandemic situation, giving Australia the capability to pivot quickly and manufacture critical vaccines within months if new or emerging pathogens arise. Its initial focus is on respiratory illnesses, with the COVID-19 vaccine first to roll off the production line, followed by a respiratory syncytial virus (RSV) vaccine, and with future plans for a flu-COVID combination candidate pending regulatory approval.
“The government saw the need for pandemic preparedness,” Harrington said, “but as you’d know, you can’t just build a facility for the next pandemic and leave it sitting there cold. The model has to be sustainable – producing vaccines for seasonal illnesses like flu and COVID keeps that skill base operating.”
This flexibility is central to Moderna’s manufacturing philosophy. The site has been built with modularity and automation in mind, ensuring that it can adapt production lines swiftly without compromising quality or throughput.
Unlike the vessel-filled plants of traditional biopharma manufacturing, the company’s operation was designed to achieve high output from a compact footprint. The modular layout enables agile scaling while reducing overheads and resource intensity.
The plant features high-speed automated filling lines, as well as an automated visual inspection system and a dedicated packaging line. Single-use technologies are used throughout, enabling rapid changeovers between products and minimising cross-contamination risk.
“For the footprint that we have, each drug substance batch can produce up to four million doses with an approximate 60-day turnaround from manufacturing to release,” Harrington said. “It’s a much shorter timeframe for both manufacturing and release, and that will allow us to respond quickly and efficiently.”
Alongside advanced robotics, digital monitoring systems feed real-time data into quality control platforms, enabling immediate adjustments and predictive maintenance.
“The automation and digital systems here give us a level of precision and agility that’s unmatched,” Harrington said. “It also means our team can focus more on high-value activities – innovation, validation, and ensuring that everything we make meets the strictest global standards.”
These advances illustrate how far biomanufacturing has evolved. Automation now underpins nearly every step, from batch testing to packaging logistics, driving both consistency and scalability. Harrington said for a facility that must operate continuously rather than being mothballed between emergencies, efficiency is important.
Behind the advanced machinery sits a highly trained, multidisciplinary workforce. Across the full Moderna Technology Centre, around 130 to 140 personnel are employed, spanning drug-substance and drug-product manufacturing, quality assurance, engineering, supply chain management, and R&D.
All employees undergo specialised training in Good Manufacturing Practice (GMP) and mRNA production processes, ensuring that standards remain aligned with global best practice. Harrington said the emphasis on training has built one of the most skilled teams in Australia’s life sciences sector.
“We’ve built a relatively small but nimble team, and their specialised knowledge means every batch produced here meets the highest international safety and quality standards,” she said.
Quality is embedded at every stage. Each vaccine batch undergoes multiple rounds of testing, from raw materials through to finished product release, and is reviewed both internally and by the Therapeutic Goods Administration (TGA) before reaching the public.
The facility’s development was made possible by close collaboration with both the Victorian and Federal Governments, who viewed sovereign mRNA vaccine capability as a cornerstone of national health security. The Victorian Government’s initiative mRNA Victoria was instrumental, positioning the state as a hub for RNA-based research and manufacturing.
Moderna also works alongside Monash University through the newly established mRNA Workforce Training Centre and the Quantitative Pharmacology Accelerator, which focus on developing advanced skills and translational research capacity within the local ecosystem. In addition, Moderna will invest $266 million in national R&D initiatives over the decade to 2033, supporting research partnerships, clinical trials, and workforce development.
Harrington said this ecosystem approach is critical to sustainability.
“You can’t just have the manufacturer standing alone. Building partnerships with universities and government ensures we grow the talent pipeline and keep Australia at the forefront of biopharmaceutical innovation.”
A new catalyst for the economy
Beyond the health imperative, the economic case for domestic mRNA production is compelling. According to Australia’s mRNA Advantage – Jobs, Health and Economic Resilience, an independent report by Oxford Economics, the Moderna Technology Centre is expected to boost GDP by $220 million annually, supporting nearly 1,000 ongoing jobs directly and indirectly, and strengthening supply chains across multiple industries.
During construction between 2022 and 2024, the project supported 1,830 jobs per year and contributed $493 million to national GDP. Once operational, it is projected to generate $96 million in direct GDP each year, with a further $124 million in flow-on activity across professional, scientific, and technical services, manufacturing, retail, and logistics.
The report also estimates that the facility could help Australia avoid up to $4.8 billion in costs over 30 years by reducing reliance on imports, preventing lockdowns, and improving health outcomes in future pandemics. Around $1.33 billion of that figure stems from avoided lockdown costs, while $3.47 billion reflects health and wellbeing benefits such as reduced hospitalisations and mortality.
“The figure represents the value of being prepared,” Harrington said. “Local production means vaccines can be manufactured and distributed faster, really minimising disruption, reducing economic loss, and improving public health outcomes.”
A large proportion of this $4.8 billion preparedness benefit stems from shortened vaccine rollout times during a health emergency. Faster domestic manufacturing means fewer weeks of lockdown and earlier population-wide immunity. The report estimates that by eliminating delays like those seen in 2021, Australia could avoid losses equivalent to $82 million per year in GDP terms – and reduce the human cost associated with delayed access to vaccines.
Harrington described the Melbourne site as “a warm base platform” – one that remains ready to scale instantly when required.
“The facility gives us the platform to grow, adapt and respond to future health challenges right here in Australia,” she said.
produce up to 100 million vaccine
doses per year in a pandemic situation.
Supporting a resilient supply chain
The MTC-M doesn’t just create vaccines; it anchors a domestic supply network that spans local suppliers, packaging partners, and research institutions. The Oxford Economics analysis found that in the operations phase, professional, scientific and technical services account for the largest share of economic contribution – about $104 million annually.
Flow-on effects extend into manufacturing, logistics, and financial services. The facility’s demand for precision components, sterile packaging, and laboratory consumables is already driving new opportunities for Australian suppliers and contract manufacturers. Harrington said building these relationships has been vital from day one.
“We’ve been really focused on developing local suppliers wherever possible,” she said. “It strengthens the ecosystem and helps ensure that if another pandemic hits, we’re not waiting on components or materials coming in from overseas.”
R&D spillovers and future therapies
While vaccines are the immediate focus, the MTC-M also serves as a springboard for broader research into oncology, rare diseases, and autoimmune conditions. Moderna’s mRNA platform can be adapted to target a range of diseases by encoding different protein sequences – a flexibility that makes it one of the most promising technologies in modern medicine.
These programmes remain in the clinical development phase, but the infrastructure and expertise established in Melbourne provide the foundation for future expansion.
“One of the advantages of mRNA technology is its flexibility,” Harrington said. “The same platform can be adapted for other therapeutic areas as research progresses.”
According to Oxford Economics, Moderna’s R&D activities are expected to generate $267 million in additional economic value nationally through productivity spillovers over the next decade, including $117 million in Victoria alone. These benefits reflect how innovation and skills developed through vaccine manufacturing extend beyond a single product line, strengthening Australia’s biomedical capability for years to come.
A model for partnership and preparedness
The creation of the Moderna Technology Centre has been described by Victorian Minister for Economic Growth and Jobs, Danny Pearson, as a “once-in-a-generation investment in jobs, medical research and health security”. It’s a statement supported by the numbers: nearly a thousand ongoing jobs, $220 million a year in GDP, and a warm-base platform capable of protecting Australians against future pandemics.
Oxford Economics’ Head of Economic Impact, Michael Brennan, put it more bluntly.
“Pandemic preparedness is not just a health priority – it’s an economic imperative,” he said. “Our modelling shows that the Moderna mRNA facility in Melbourne could save Australia billions in the event of a future health emergency by avoiding lockdowns, reducing health impacts and improving wellbeing.”
The partnership also exemplifies how government, academia, and private industry can co-invest in critical national infrastructure. With Monash University, mRNA Victoria, and federal agencies all playing a role, the facility has effectively created a new industrial category in Australia – one that blends science, technology, and advanced manufacturing.
For Harrington and her team, the focus now turns to production ramp-up and the delivery of the first Australian-made mRNA vaccines. Having secured its GMP licence from the TGA, the site expects to deliver its first batches to Australians within months.
“Our immediate focus is the respiratory vaccines portfolio,” she said. “But we’re also continuing to expand research collaborations and build local partnerships across industry and academia. Globally, mRNA science is advancing rapidly, and we’re proud that Australia is now part of that momentum.”
As the world continues to navigate evolving health threats, Moderna’s Technology Centre stands as a facility built not just for today’s needs but for whatever challenges may come next.
In combining sovereign capability with cutting-edge manufacturing, it embodies the future of Australian industry – agile, intelligent, and ready.
